Company news
Aurinia Pharmaceuticals Inc news in 2022
Aurinia Pharmaceuticals Inc's news releases, calls and decks from 2022, newest first.
Aurinia Announces the Great Britain Marketing Authorization of LUPKYNIS® (voclosporin) for the Treatment of Lupus Nephritis
November 29, 2022
Aurinia Reports Third Quarter and Nine Months 2022 Financial and Operational Results
November 2, 2022
Aurinia Pharmaceuticals to Release Third Quarter 2022 Financial and Operational Results on November 3, 2022
October 27, 2022
Aurinia Pharmaceuticals Announces Presentations at American Society of Nephrology (ASN) Kidney Week 2022
October 26, 2022
Aurinia Pharmaceuticals Announces Presentations at American College of Rheumatology (ACR) Convergence 2022
September 19, 2022
Aurinia Announces European Commission Approval of LUPKYNIS® (voclosporin) for the Treatment of Lupus Nephritis
September 18, 2022
Aurinia Reports Second Quarter and Six Months 2022 Financial and Operational Results
August 3, 2022
Aurinia Pharmaceuticals Notification Regarding Inter Partes Patent Review
July 25, 2022
Aurinia Pharmaceuticals to Release Second Quarter 2022 Financial and Operational Results on August 4, 2022
July 24, 2022
Aurinia Announces Positive CHMP Opinion for LUPKYNIS® (voclosporin) for the Treatment of Adults with Active Lupus Nephritis in Europe
July 21, 2022
Aurinia Announces the Addition of Three Seasoned Executive Leaders to Advance Company Strategy and Performance
July 13, 2022
Aurinia Presents Data Demonstrating LUPKYNIS® (voclosporin) is Effective in Achieving Proteinuria Treatment Targets in Lupus Nephritis Defined by EULAR/ERA Recommendations
June 2, 2022
Aurinia Presents Results from the Two-Year AURORA 2 Continuation Study at the 2022 European Renal Association (ERA) Congress
May 19, 2022
Aurinia Pharmaceuticals Announces Presentations at the 2022 ERA Congress and the 2022 EULAR Congress
May 15, 2022
Aurinia Reports First Quarter 2022 Financial and Operational Results
May 9, 2022
Notice of New Dial-In Numbers for Aurinia Pharmaceuticals First Quarter 2022 Financial and Operational Results on May 10, 2022
May 5, 2022
Aurinia Pharmaceuticals to Release First Quarter 2022 Financial and Operational Results on May 10, 2022
May 1, 2022
Aurinia Announces Year-Two Commitment to Patient Navigation Grant Program to Address Barriers for Individuals Living with Lupus and Lupus Nephritis
April 18, 2022
Aurinia Pharmaceuticals Announces Presentations at the 2022 National Kidney Foundation Spring Clinical Meetings
April 3, 2022
Aurinia Pharmaceuticals to Present at Upcoming Investor Conferences
March 2, 2022
Aurinia Reports Fourth Quarter and Full Year 2021 Financial Results and Company Updates
February 27, 2022
Aurinia Pharmaceuticals to Release Fourth Quarter and Year End 2021 Financial Results on February 28, 2021
February 8, 2022
Aurinia Pharmaceuticals to Present at the 11th Annual Leerink Global Healthcare Conference
February 2, 2022
Aurinia Pharmaceuticals to Present at Upcoming January Investor Conferences
January 3, 2022
Calls in 2022
Decks in 2022
- Technical Presentation (January 2022)
Technical · 10 slides · Jan 7, 2022